JP2671972B2 - 嘔吐の治療のための薬剤 - Google Patents

嘔吐の治療のための薬剤

Info

Publication number
JP2671972B2
JP2671972B2 JP6121042A JP12104294A JP2671972B2 JP 2671972 B2 JP2671972 B2 JP 2671972B2 JP 6121042 A JP6121042 A JP 6121042A JP 12104294 A JP12104294 A JP 12104294A JP 2671972 B2 JP2671972 B2 JP 2671972B2
Authority
JP
Japan
Prior art keywords
patent application
vomiting
substance
filed
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP6121042A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0753362A (ja
Inventor
マノイ・シー・デサイ
ジョン・エイ・ロウ,ザ・サード
ジョン・ダブリュー・ワトソン
Original Assignee
フアイザー・インコーポレイテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フアイザー・インコーポレイテツド filed Critical フアイザー・インコーポレイテツド
Publication of JPH0753362A publication Critical patent/JPH0753362A/ja
Application granted granted Critical
Publication of JP2671972B2 publication Critical patent/JP2671972B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
JP6121042A 1993-06-04 1994-06-02 嘔吐の治療のための薬剤 Expired - Fee Related JP2671972B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US072629 1993-06-04
US08/072,629 US5393762A (en) 1993-06-04 1993-06-04 Pharmaceutical agents for treatment of emesis

Publications (2)

Publication Number Publication Date
JPH0753362A JPH0753362A (ja) 1995-02-28
JP2671972B2 true JP2671972B2 (ja) 1997-11-05

Family

ID=22108825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6121042A Expired - Fee Related JP2671972B2 (ja) 1993-06-04 1994-06-02 嘔吐の治療のための薬剤

Country Status (19)

Country Link
US (1) US5393762A (cg-RX-API-DMAC10.html)
EP (1) EP0627221B1 (cg-RX-API-DMAC10.html)
JP (1) JP2671972B2 (cg-RX-API-DMAC10.html)
KR (1) KR100190729B1 (cg-RX-API-DMAC10.html)
CN (1) CN1100535C (cg-RX-API-DMAC10.html)
AT (1) ATE209490T1 (cg-RX-API-DMAC10.html)
AU (1) AU666077B2 (cg-RX-API-DMAC10.html)
CA (1) CA2124990C (cg-RX-API-DMAC10.html)
DE (1) DE69429208T2 (cg-RX-API-DMAC10.html)
DK (1) DK0627221T3 (cg-RX-API-DMAC10.html)
ES (1) ES2164088T3 (cg-RX-API-DMAC10.html)
HU (1) HU222243B1 (cg-RX-API-DMAC10.html)
IL (1) IL109802A (cg-RX-API-DMAC10.html)
MY (1) MY115310A (cg-RX-API-DMAC10.html)
NZ (1) NZ260674A (cg-RX-API-DMAC10.html)
PT (1) PT627221E (cg-RX-API-DMAC10.html)
RU (1) RU2135179C1 (cg-RX-API-DMAC10.html)
TW (1) TW318791B (cg-RX-API-DMAC10.html)
ZA (1) ZA943896B (cg-RX-API-DMAC10.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9206073A (pt) * 1991-05-31 1994-12-06 Pfizer Derivados de quinuclidina
SK282203B6 (sk) * 1991-06-20 2001-12-03 Pfizer Inc. Fluoroalkoxybenzylamínové deriváty heterocyklov obsahujúcich dusík, spôsob ich prípravy, medziprodukty, spôsob prípravy medziproduktov, použitie a farmaceutický prostriedok
ES2149767T5 (es) 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
EP0687268B1 (en) * 1993-03-04 1998-05-27 Pfizer Inc. Spiroazacyclic derivatives as substance p antagonists
GB9305718D0 (en) 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
DE69617226T2 (de) * 1995-03-27 2002-07-25 Hisamitsu Pharmaceutical Co., Inc. Piperidinderivate.
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW458774B (en) * 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
US6329396B1 (en) 1996-06-10 2001-12-11 Pfizer Inc. Substituted benzylaminopiperidine compounds
GB9708484D0 (en) 1997-04-25 1997-06-18 Merck Sharp & Dohme Therapeutic agents
AU736542B2 (en) * 1997-06-27 2001-08-02 Merck Sharp & Dohme Limited Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents
EP1145714A4 (en) * 1998-11-27 2004-12-15 Takeda Chemical Industries Ltd DRUGS
IL133077A0 (en) * 1999-01-29 2001-03-19 Pfizer Prod Inc Azithromycin combination for emesis control in dogs
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
RU2197961C2 (ru) * 2000-07-17 2003-02-10 Центр по разработке эластомеров Казанского государственного технологического университета Средство для профилактики и купирования тошноты и рвоты
RU2183118C1 (ru) * 2001-07-12 2002-06-10 Государственный научный центр РФ Институт медико-биологических проблем РАН Способ профилактики вестибуловегетативных расстройств у человека в условиях воздействий, вызывающих укачивание
EP1411946A1 (en) * 2001-07-20 2004-04-28 Pfizer Products Inc. Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses
BRPI0507325A (pt) * 2004-01-30 2007-07-03 Pfizer Prod Inc antagonistas dos receptores nk-1 para melhorar a recuperação da anestesia
HUE034099T2 (en) * 2004-01-30 2018-01-29 Zoetis Services Llc Antimicrobial preservatives for the delivery of multidose formulations using beta-cyclodextrins for liquid dosage forms
DK1713801T3 (da) * 2004-02-02 2008-03-17 Pfizer Prod Inc Fremgangsmåde til fremstilling af 1-(2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amin
WO2014197137A1 (en) * 2013-04-29 2014-12-11 Howard Brooks-Korn Diversion-resistant formulation
WO2018175670A1 (en) 2017-03-22 2018-09-27 The Research Foundation For The State University Of New York Matrix metalloproteinase-9 hemopexin domain inhibitors and methods of treatment using same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8527052D0 (en) * 1985-11-02 1985-12-04 Beecham Group Plc Compounds
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
JPH072740B2 (ja) * 1990-06-01 1995-01-18 フアイザー・インコーポレイテツド 3―アミノ―2―アリールキヌクリジン
DE69106365T2 (de) * 1990-07-23 1995-05-04 Pfizer Chinuclidinderivate.
ATE121389T1 (de) * 1990-09-28 1995-05-15 Pfizer Ringverknüpfte analoge von stickstoffenthaltenden nichtaromatischen heterocyclen.
CA2100163A1 (en) * 1991-01-10 1992-07-11 John A. Lowe, Iii N-alkyl quinuclidinium salts
DE69200921T2 (de) * 1991-03-01 1995-05-04 Pfizer 1-azabicyclo[3.2.2]nonan-3-aminderivate.
AU647592B2 (en) * 1991-03-26 1994-03-24 Pfizer Inc. Stereoselective preparation of substituted piperidines
RU2092486C1 (ru) * 1991-05-22 1997-10-10 Пфайзер Инк. Замещенные 3-аминохинуклидины
BR9206073A (pt) * 1991-05-31 1994-12-06 Pfizer Derivados de quinuclidina
SK282203B6 (sk) * 1991-06-20 2001-12-03 Pfizer Inc. Fluoroalkoxybenzylamínové deriváty heterocyklov obsahujúcich dusík, spôsob ich prípravy, medziprodukty, spôsob prípravy medziproduktov, použitie a farmaceutický prostriedok
TW202432B (cg-RX-API-DMAC10.html) * 1991-06-21 1993-03-21 Pfizer
ES2149767T5 (es) * 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
EP0607164B1 (en) * 1991-09-26 2002-05-02 Pfizer Inc. Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists
ES2111650T3 (es) * 1991-11-12 1998-03-16 Pfizer Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
JP2656702B2 (ja) * 1992-03-23 1997-09-24 ファイザー製薬株式会社 ペプチド性キヌクリジン
DE69331190T2 (de) * 1992-05-18 2002-04-18 Pfizer Inc., New York Überbrückte azabicyclische derivate als substanz p antagonisten
ES2147759T3 (es) * 1992-12-10 2000-10-01 Pfizer Heterociclos no aromaticos sustituidos con aminometileno y uso como antagonistas de la sustancia p.
EP0687268B1 (en) * 1993-03-04 1998-05-27 Pfizer Inc. Spiroazacyclic derivatives as substance p antagonists
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
AU5776099A (en) * 1998-08-14 2000-03-06 Via, Inc. Mobile robotic snake

Also Published As

Publication number Publication date
US5393762A (en) 1995-02-28
DK0627221T3 (da) 2002-02-11
IL109802A (en) 2002-04-21
CA2124990C (en) 1999-04-20
KR950000144A (ko) 1995-01-03
DE69429208T2 (de) 2002-05-23
JPH0753362A (ja) 1995-02-28
PT627221E (pt) 2002-04-29
TW318791B (cg-RX-API-DMAC10.html) 1997-11-01
AU6452194A (en) 1994-12-15
ZA943896B (en) 1995-12-04
RU94020410A (ru) 1996-05-10
HU9401676D0 (en) 1994-09-28
CN1121806A (zh) 1996-05-08
HU222243B1 (hu) 2003-05-28
NZ260674A (en) 2000-07-28
AU666077B2 (en) 1996-01-25
HUT71550A (en) 1995-12-28
ES2164088T3 (es) 2002-02-16
IL109802A0 (en) 1994-08-26
KR100190729B1 (ko) 1999-06-01
EP0627221A3 (en) 1995-08-02
RU2135179C1 (ru) 1999-08-27
EP0627221B1 (en) 2001-11-28
DE69429208D1 (de) 2002-01-10
EP0627221A2 (en) 1994-12-07
CN1100535C (zh) 2003-02-05
ATE209490T1 (de) 2001-12-15
MY115310A (en) 2003-05-31

Similar Documents

Publication Publication Date Title
EP0627221B1 (en) Substance P antagonists for the treatment of emesis
US5102887A (en) Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US20010006972A1 (en) Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
AU717776B2 (en) NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
JP7581233B2 (ja) 神経障害性疼痛の治療方法
SK12793A3 (en) Heterocyclic compounds, process for their preparation and their using
EP0873753A1 (en) Use of NK-1 receptor antagonists for the manufacture of a medicament in the treatment of symptoms of irritable bowel syndrome
HUT60270A (en) Process for producing alpha-oxoacetamide derivatives and pharmaceutical compositions comprising such derivatives as active ingredient
US5340826A (en) Pharmaceutical agents for treatment of urinary incontinence
CA2488311A1 (en) Combination treatment for depression and anxiety by nk1 and nk3 antagonists
US5750535A (en) Pharmaceutical agents for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
AU751590B2 (en) Acetylcholine enhancers
US20040180890A1 (en) Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same
EA000531B1 (ru) Активное вещество при производстве фармацевтического препарата для лечения травматического повреждения головного мозга
JP2955550B2 (ja) 後発性嘔吐の治療のためのnk−1レセプタ−アンタゴニスト
EP0659409A2 (en) Substance 1 antagonists for the inhibition of angiogenesis
SK8792002A3 (en) Quinoline-based compound, pharmaceutical composition containing same and use thereof
JPS5973521A (ja) 恐慌障害の治療用組成物
AU7177100A (en) NK-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
CA2324116A1 (en) Nk-1 receptor antagonists and eletriptan for the treatment of migraine
CA2205016A1 (en) Nk-1 receptor antagonists for the treatment of eye disorders

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20070711

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080711

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080711

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090711

Year of fee payment: 12

LAPS Cancellation because of no payment of annual fees